Indeed, although HIF-2 is pro-tumourigenic, with its targeting recently approved as a treatment for VHL syndrome-associated tumours (14), HIF-1 is generally considered a tumour suppressor in ccRCC (15). The gene discussed is HIF1A; the disease is nonpapillary renal cell carcinoma.